Genomic diagnostic startup Medomics plans to launch next month a mitochondrial genome sequence-analysis test for mitochondrial diseases that runs on a second-generation sequencing platform. The test, it says, will be more sensitive than current sequencing-based mitochondrial genome tests.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.